دورية أكاديمية
أعرض في EDS

BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.

التفاصيل البيبلوغرافية
العنوان: BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
المؤلفون: Jiang L; Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China., Yang P; Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China., Liu Y; Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China., Li J; Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China. dr.lijuan@hotmail.com.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Mar 27; Vol. 150 (3), pp. 162. Date of Electronic Publication: 2024 Mar 27.
نوع المنشور: Case Reports; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Imidazoles*, Humans ; Proto-Oncogene Proteins B-raf/genetics ; Oximes/therapeutic use ; Mutation ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Mitogen-Activated Protein Kinase Kinases/genetics ; Mitogen-Activated Protein Kinase Kinases/therapeutic use
مستخلص: BRAF mutations are found in 1-5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic NSCLC carrying BRAF V600E mutations. Preclinical studies have shown that dabrafenib + trametinib may also have inhibitory effects on some types of non-V600E mutations, especially some class II BRAF mutations. However, the efficacy of dabrafenib + trametinib on non-V600E mutant NSCLC in clinical practice only exists in some case reports. Here, we report a case of NSCLC patient carrying BRAF ex15 p.T599dup, who showed a clinical response to the combined therapy of dabrafenib + trametinib.
(© 2024. The Author(s).)
References: Bracht J, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ et al (2019) BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: the need for a new pre-clinical treatment rationale. Cancers (basel) 11(9):1381. https://doi.org/10.3390/cancers11091381. (PMID: 10.3390/cancers1109138131533235)
Frisone D, Friedlaender A, Malapelle U, Banna G, Addeo A (2020) A BRAF new world. Crit Rev Oncol Hematol 152:103008. https://doi.org/10.1016/j.critrevonc.2020.103008. (PMID: 10.1016/j.critrevonc.2020.10300832485528)
Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB et al (2020) Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. J Thorac Oncol 15(10):1611–1623. https://doi.org/10.1016/j.jtho.2020.05.021. (PMID: 10.1016/j.jtho.2020.05.021325404097529990)
Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N et al (2018) FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist 23(6):740–745. https://doi.org/10.1634/theoncologist.2017-0642. (PMID: 10.1634/theoncologist.2017-0642294380936067947)
O’Leary CG, Andelkovic V, Ladwa R, Pavlakis N, Zhou C, Hirsch F et al (2019) Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 8(6):1119–1124. https://doi.org/10.21037/tlcr.2019.10.22. (PMID: 10.21037/tlcr.2019.10.22320105896976351)
Owsley J, Stein MK, Porter J, In GK, Salem M, O’Day S et al (2021) Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood) 246(1):31–39. https://doi.org/10.1177/1535370220959657. (PMID: 10.1177/153537022095965733019809)
Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S et al (2020) Current advances in the treatment of BRAF-mutant melanoma. Cancers (basel) 12(2):482. https://doi.org/10.3390/cancers12020482. (PMID: 10.3390/cancers1202048232092958)
Poulikakos PI, Sullivan RJ, Yaeger R (2022) Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res 28(21):4618–4628. https://doi.org/10.1158/1078-0432.CCR-21-2138. (PMID: 10.1158/1078-0432.CCR-21-2138354860979616966)
Reyes R, Mayo-de-Las-Casas C, Teixidó C, Cabrera C, Marín E, Vollmer I et al (2019) Clinical benefit from BRAF/MEK inhibition in a double non-V600E BRAF mutant lung adenocarcinoma: a case report. Clin Lung Cancer 20(3):e219–e223. https://doi.org/10.1016/j.cllc.2019.02.022. (PMID: 10.1016/j.cllc.2019.02.02230926357)
Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H (2020) Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes (basel) 11(11):1342. https://doi.org/10.3390/genes11111342. (PMID: 10.3390/genes1111134233198372)
Su PL, Lin CY, Chen YL, Chen WL, Lin CC, Su WC (2021) Durable response to combined dabrafenib and trametinib in a patient with BRAF K601E mutation-positive lung adenocarcinoma: a case report. JTO Clin Res Rep 2(8):100202. https://doi.org/10.1016/j.jtocrr.2021.100202. (PMID: 10.1016/j.jtocrr.2021.100202345900458474392)
Turshudzhyan A, Vredenburgh J (2020) A rare p.T599dup BRAF mutant NSCLC in a non-smoker. Curr Oncol 28(1):196–202. https://doi.org/10.3390/curroncol28010021. (PMID: 10.3390/curroncol28010021337041867816189)
فهرسة مساهمة: Keywords: BRAF; Case report; NSCLC; Non-V600; p.T599dup
المشرفين على المادة: QGP4HA4G1B (dabrafenib)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
0 (Oximes)
EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
EC 2.7.11.1 (BRAF protein, human)
0 (Imidazoles)
تواريخ الأحداث: Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240413
رمز التحديث: 20240413
مُعرف محوري في PubMed: PMC10972996
DOI: 10.1007/s00432-024-05675-9
PMID: 38538919
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-024-05675-9